newsUK CMA disqualifies pharma company director after breaking competition law15 June 2020 | By Victoria Rees (European Pharmaceutical Review)A pharmaceutical company director is now banned from holding a director role at any UK company for the next five years after making illegal arrangements.
newsTiofarma admits role in illegal agreement causing fludrocortisone price hikes27 January 2020 | By Hannah Balfour (European Pharmaceutical Review)The CMA has announced Tiofarma admits taking part in an anti-competitive agreement with Amilco and Aspen which resulted in huge price increase in fludrocortisone acetate tablets.
newsCMA accuses three pharma companies of illegal market agreement4 October 2019 | By Victoria Rees (European Pharmaceutical Review)The UK Competition and Markets Authority has alleged that Aspen paid two other pharmaceutical companies to ensure they were the only supplier of a drug to the NHS.
